Making DNA Is Now Cheap And Easy, And That Could Pose Security Risks : Shots - Health News Labs are churning out more and more synthetic DNA for scientists who want to use it to reprogram cells. Some say the technology has outpaced government safety guidelines put in place a decade ago.

As Made-To-Order DNA Gets Cheaper, Keeping It Out Of The Wrong Hands Gets Harder

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript


DNA encodes all of our genetic information. So you might find it surprising that it is getting easier to make DNA in a lab. In fact, some companies are cranking out huge amounts of cheap, made-to-order DNA. So what are the chances, though, that it could be misused? NPR's Nell Greenfieldboyce takes a look.

NELL GREENFIELDBOYCE, BYLINE: DNA is amazing. It's a kind of code made up of molecules known by their first letters - A, C, G and T. Strung together, these letters can form genes, biological instructions that can get cells to do stuff, like make insulin or grow hair.

Patrick Boyle is showing me around a Boston biotech company called Gingko Bioworks.

PATRICK BOYLE: You know, I finished my Ph.D. in 2012, and over my - the course of my entire Ph.D., working with a few other people, we synthesized six genes.

GREENFIELDBOYCE: But, oh, how times have changed.

BOYLE: Today, we're synthesizing more than 10,000 genes every month.

GREENFIELDBOYCE: The workers here are like computer programmers, only the code they write is DNA code. Their designer DNA gets inserted into cells, like bacteria, yeast, fungi, to try to make them spew out chemicals that can be used as new drugs or food ingredients.

BOYLE: We're coming up with thousands of new designs on a computer, printing out the DNA for them, booting up that DNA, seeing what it does and then iterating on those designs.

GREENFIELDBOYCE: When he says printing out DNA, he means it literally.


GREENFIELDBOYCE: The technology used for inkjet printing has been adapted to print short fragments of DNA onto glass slides. Those fragments then get assembled into larger and larger pieces in a highly automated process.

BOYLE: So many of the robots that you see behind you are basically pipetting, you know, liquid around to put different fragments together to build the correct, full design.

GREENFIELDBOYCE: Over the last decade, the cost of making a pair of DNA letters - those A, C, T and Gs - has dropped from $1 to less than 10 cents.

BOYLE: We can actually, finally, afford to write this code, and we can write much more of it.

GREENFIELDBOYCE: This company now uses so much DNA, it not only makes its own but also buys some from another manufacturer named Twist Bioscience. Its CEO is Emily Leproust. She says her company's other customers are pharmaceutical firms, agricultural companies and academic scientists trying to understand basic biology. Anyone can just order DNA online.

EMILY LEPROUST: So you log on the website, you upload the sequence you want and you can order one gene or 10 genes or a thousand genes.

GREENFIELDBOYCE: A couple weeks later, your custom DNA arrives in the mail. At least, it does if your order gets through this company's rigorous security screening. Because here's the thing - DNA is so powerful that it's potentially dangerous. Someone could use it to transform a harmless bacteria into one that makes a deadly toxin. And bits of DNA can be assembled into a virus, like Ebola. Twist director of biosecurity is James Diggans. He says they check out every potential customer and each requested DNA sequence, looking to see if there's anything worrisome in there, like a gene specific to some nasty germ.

JAMES DIGGANS: And then we make a decision about whether that sequence is appropriate to make for that customer.

GREENFIELDBOYCE: A handful of times, they've said no. Diggans won't give specifics. He does say they would not have made the pieces of DNA that one research team recently ordered from a different company and used to assemble the horsepox virus. This was controversial because horsepox is so close to the deadly human pathogen smallpox.

DIGGANS: That is not something we would have been comfortable in producing.

GREENFIELDBOYCE: This just illustrates a key issue - companies have different standards. Many, but not all, follow some biosecurity guidelines put out by the U.S. government that were designed to keep people from doing anything dodgy.

Those guidelines came out about a decade ago and are kind of out of date. For example, the guidelines call for screening only big chunks of DNA. Diggans says, it's gotten so easy to put little pieces together, they really need to be screened as well.

DIGGANS: And so we think that's sort of an easy next step that the U.S. government could take.

GREENFIELDBOYCE: There's also new desktop DNA synthesizers. Rather than ordering from a company, scientists can now buy one of these machines to create desired bits of DNA in their own lab.

DIGGANS: That machine needs to be able to screen and ensure that that manufacture occurs safely and legally.

GREENFIELDBOYCE: Just like photocopier machines have built-in controls to stop people from counterfeiting money.

Gigi Gronvall is a biosecurity expert at the Center for Health Security at Johns Hopkins University. She agrees that the government should strengthen its guidelines and thinks all researchers who receive federal funding should be required to order their synthetic DNA from companies that follow them.

GIGI GRONVALL: The idea there is to level the playing field, so to make the business case that screening is not a burden for the companies, it becomes an advantage.

GREENFIELDBOYCE: Still, she says, these measures are only a partial solution.

GRONVALL: It's going to be something that should be done to deter some people who might misuse these technologies. It's not going to get everybody.

GREENFIELDBOYCE: Just because the technology is advancing rapidly and is available around the world.

A spokesperson for the Department of Health and Human Services said that officials are in the process of reviewing and updating the guidelines for synthetic DNA manufacturers but that it was too early to discuss what changes might be made.

Nell Greenfieldboyce, NPR News.


Copyright © 2019 NPR. All rights reserved. Visit our website terms of use and permissions pages at for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.